Treatment of diarrhea caused by Cryptosporidium parvum:: A prospective randomized, double-blind, placebo-controlled study of nitazoxanide
Treatment of diarrhea caused by Cryptosporidium parvum:: A prospective randomized, double-blind, placebo-controlled study of nitazoxanide
复制标题
DOI：
10.1086/321008
复制
发表时间：
2001-07-01
影响因子：
6.4
通讯作者：
Ayers, MS
中科院分区：
文献类型：
--
作者：
Rossignol, JFA;Ayoub, A;Ayers, MS
在来自埃及尼罗河三角洲的50名成人和50名儿童中进行了一项前瞻性随机、双盲、安慰剂对照研究，以评价硝唑尼特治疗隐孢子虫引起的腹泻的疗效。在成人和青少年中给予500 mg剂量的硝唑尼特，每日两次，持续3天;在4-11岁儿童中给予200 mg剂量的硝唑尼特，每日两次，持续3天;在1-3岁儿童中给予100 mg剂量的硝唑尼特，每日两次，持续3天。在开始治疗后7天，硝唑尼特治疗组49例患者中有39例（80%）腹泻消退，而安慰剂组49例患者中有20例（41%）腹泻消退（P
A prospective randomized, double-blind, placebo-controlled study was conducted in 50 adults and 50 children from the Nile delta of Egypt, to evaluate the efficacy of nitazoxanide in treating diarrhea caused by Cryptosporidium parvum. Nitazoxanide was administered in 500-mg doses twice daily for 3 days in adults and adolescents, in 200-mg doses twice daily for 3 days in children aged 4-11 years, and in 100-mg doses twice daily for 3 days in children aged 1-3 years. At 7 days after initiation of therapy, diarrhea had resolved in 39 (80%) of the 49 patients in the nitazoxanide treatment group, compared with 20 (41%) of 49 in the placebo group (P